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Abstract 
MicroRNAs(miRNAs) are emerging as important regulators in tumorigenesis. Increasing 
evidences  have  indicated  microRNA-7(miR-7)  to  be  a  potential  tumor  suppressor  in 
several human cancers. However, only a limited number of target genes have been iden-
tified so far and its biological function in Non-Small Cell Lung Cancer (NSCLC) remains 
to be further elucidated. In the present study, we observed a reduction of miR-7 level in 
NSCLC cell lines. Overexpression of miR-7 not only suppressed NSCLC A549 cells pro-
liferation, induced cell apoptosis and inhibited cell migration in vitro, but also reduced 
tumorigenicity in vivo. Bioinformatics predictions revealed a potential binding site of 
miR-7 on 3'UTR of BCL-2 and it was further confirmed by luciferase assay. Moreover, 
subsequent experiments showed that BCL-2 was downregulated by miR-7 at both tran-
scriptional and translational levels. These results suggest that miR-7 regulates the ex-
pression of BCL-2 through direct 3’UTR interactions. Therefore, we postulate BCL-2 to be 
a novel target possibly involved in miR-7-mediated growth suppression and apoptosis of 
A549 cells. These findings may provide a basic rationale for the use of miR-7 in the 
treatment of NSCLC. 
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Introduction 
MiRNAs are a group of non-coding small RNAs 
produced from actual genes within the genomic loci 
of cells[1, 2]. The primary transcripts of miRNAs are 
processed  by  Drosha  to  form  70–80nt  precursor 
miRNAs, which are then exported to the cytoplasm 
and  processed  by  Dicer  into  mature  microRNAs. 
Mature miRNAs regulate their target genes through 
partial sequence complementarity to the 3’ untrans-
lated region (UTR) of target genes, thereby resulting 
in  mRNA  degradation  or/and  translational  repres-
sion[3, 4].  
As a new layer of gene-regulation mechanism, 
miRNAs  are  emerging  as  key  regulators  in  patho-
genesis of cancer[5]. By regulating the expression of 
their  target  genes,  miRNAs  profoundly  influence  a 
wide  variety  of  pathways,  thereby  acting  as  onco-
genes or tumor suppressors[6, 7]. Indeed, a number of 
differentially regulated miRNAs, such as miR-155[8, 
9],  let-7a[10],  miR-21[8],  miR-34a[11]  and 
miR-7[12-16], have been identified to be functionally 
associated with cancer cell proliferation, invasion and 
metastasis. Among them, miR-7 is suggested to be a 
putative tumor suppressor in breast and glioblasto-
ma[12, 13, 15]. However, the biological function and 
mechanisms  of  miR-7  in  lung  cancer,  especially  in 
NSCLC, remain to be further elucidated. 
Ivyspring  
International Publisher   Int. J. Biol. Sci. 2011, 7 
 
http://www.biolsci.org 
806 
In the present study, we demonstrated a reduc-
tion of miR-7 level in NSCLC cell lines. Overexpres-
sion of miR-7 suppressed NSCLC A549 cells prolifer-
ation, induced A549 cells apoptosis, inhibited cancer 
cell migration in vitro, and reduced tumorigenicity in 
vivo.  Subsequent  experiments  confirmed  that  miR-7 
downregulated the expression of BCL-2 at both tran-
scriptional  and  translational  levels  through  direct 
3’UTR interactions. These results suggested BCL-2 to 
be a novel target through which miR-7 inhibits A549 
cells proliferation. 
Materials and methods 
Cell lines and cell culture 
A549, H1299, H1355, H460, MRC5 and 293T cell 
lines were provided by Institute of Biochemistry and 
Cell Biology of Chinese Academy of Science (China) 
and originated from ATCC. All cells were grown in 
DMEM supplemented with 10% fetal bovine serum, 2 
μM glutamine, 100 IU/ml penicillin, and 100μg/ml 
streptomycin sulfate. 
RNA extraction 
Total RNA of cultured cells was extracted with 
TRIzol  reagent  (Invitrogen,  Carlsbad,  CA, USA)  ac-
cording to the manufacturer’s protocol. RNAs were 
then stored at -80℃ before RT-PCR analysis. 
Quantitative RT-PCR (qRT-PCR) for miRNA 
For  mature  miRNA  expression  analysis,  ap-
proximately 10 ng of RNA was converted to cDNA 
using the ABI miRNA reverse transcription kit (Ap-
plied  Biosystems,  Foster  City,  CA)  along  with 
miR-7-specific  primers  (Applied  Biosystems,  Foster 
City,  CA).  After  reverse  transcription,  quantitative 
polymerase chain reaction (PCR) was performed on 
the ABI 7500 thermocycler (Applied Biosystems, Fos-
ter City, CA) according to the manufacture’s protocol. 
U6 gene was used as a normalization control for all 
samples. 
qRT-PCR for mRNA expression 
Synthesis of cDNA was performed on 1μg of to-
tal RNA per sample with the primerScript RT reagent 
Kit (TaKaRa, Dalian, China) according to the manu-
facturer’s  manual.  Quantitative  reverse  transcrip-
tion-PCR was performed in triplicate for each sample 
by FastStart Universal SYBR Green Master kit (Roche, 
Switzerland) according to the manufacturer’s instruc-
tions.  Oligonucleotides  were  designed  by  the  Pri-
merExpress software. GAPDH was used as a house-
keeping  gene  for  normalization.  The  sequences  of 
primers in this section are the followings: (1) BCL-2: 
5’-ATGTGTGTGGAGAGCGTCAACC-3’  (forward) 
and  5’-TGAGCAGAGTCTTCAGAGACAGCC-3’  (re-
verse);  (2)  GAPDH:  5’-TGCACCACCAACTGC 
TTAGC-3’  (forward)  and  5’-GCATGGACTGTG 
GTCATGAG-3’  (reverse);  (3)  MMP-2:  5’-CCAACAC 
TGGGACCTGTCACTC-3’ (forward) and 5’-TGTCAC 
TGTCCGCCAAATAAACC-3’  (reverse);  (4)  MMP-9: 
5’-TGGGCTACGTGACCTATGACAT-3’  (forward) 
and  5’-GCCCAGCCCACCTCCACTCCTC-3’  (re-
verse). 
MiRNAs mimic and transfection 
The  human  miR-7  duplex  mimic  (miR-7)  and 
negative  control  oligonucleotide  duplex  mimic 
(miR-NC)  were  designed  and  provided  by  Ribobio 
(Guangzhou,  Guangdong,  China).  30-50%  confluent 
cells were transfected with miRNAs by Lipofectamine 
2000 (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s protocol. Total RNA was extracted 24 
hours  after  transfection,  and  total  cell  protein  were 
extracted 48 or 72 hours after transfection. 
Cell proliferation assay  
Cell proliferation assay was determined by Cell 
Counting Kit-8 assay (Dojindo, Japan), a redox assay 
similar  to  3-(4,5-dimethylthiazol-2-yl)-2,5-  diphenyl-
tetrazolium bromide (MTT) according to the manu-
facture’s protocol. Cell proliferation assay was carried 
out in hexakis. 
Apoptotic morphology by DAPI staining  
Cells  were  stained  with 
4,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich) 
and those with fragmented or condensed nuclei were 
defined as apoptotic cells. At least five visual fields 
were  observed  under  fluorescence  microscope  for 
each sample. 
Caspase 3/7 assay 
Caspase 3/7 activity was performed by manu-
facture’s protocol of Caspase 3/7 assay (Pierce, USA). 
Briefly, cells cultured in a white-walled 96-well plate 
were  added  with  100μL  of  Caspase-Glo®  3/7  Rea-
gent. Mix gently and incubate the cells at room tem-
perature for 30 minutes to 3 hours, then measure the 
luminescence  of  each  sample  in  a  plate-reading  lu-
minometer of Tecan´s Infinite M200. Caspase 3/7 as-
say was carried out in triplicate. 
Vector constructs  
To construct BCL-2-3’UTR plasmid, a wild-type 
3’-UTR fragment of human BCL-2 mRNA (1384-1390 
nt,  Genbank  accession  no.NM_000633.2)  containing 
the putative miR-7 binding sequence was amplified 
by PCR and cloned into the site between  XbaI and 
FseI  of  the  pGL3-control  vector  (Promega,  USA) Int. J. Biol. Sci. 2011, 7 
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which  is  the  downstream  of  the  luciferase  reporter 
gene. A mutant of the single miR-7 binding site (5’- 
AGUCUUC-3’  to  5’-  AccCggC-3’)  in  the  3’-UTR  of 
BCL-2 was included by Site-Directed Mutagenesis Kit 
(SBS Genetech, Beijing, China). Wild and mutant type 
of  pGL3-con-BCL-2-UTR  vectors  were  validated  by 
DNA  sequencing.  The  nucleotide  sequences  of  pri-
mers  for  BCL-2-3’UTR  clone  were: 
5’-gctctagagcGCCACAAGTGAAGTCAACA-3’  (for-
ward) and 5’-tataggccggcctaACAGGCACAGAACAT 
CCAG-3’ (reverse) and the two pairs of mutagenesis 
primers  were:  (1)  5’-GAGTCAGGATGCTGTC 
TgCgCACGAATAGTACTCAGT-3’(forward)  and  5’ 
ACTGAGTACTATTCGTGcGcAGACAGCATCCTG 
ACTC-3’(reverse);  (2)  5’-GAGTCAGGATGCTGTCc 
GcGCACGAATAGTACTCAGT-3’  (forward)  and  5’ 
ACTGAGTACTATTCGTGCgCgGACAGCATCCTG 
ACTC-3’ (reverse). 
Lentiviral vector production, titration and 
transduction 
The  pre-hsa-miR-7-1  sequence  was  obtained 
from human genomic DNA by PCR with the follow-
ing  primers:  5’-GGGCCCGCTCTAGACTC 
GAGATATTTGCATGTCGCTATGTG-3’  (forward) 
and  5’-CGCGGCCGCCTAATGGATCCAAAAA 
AGGCACAGTCGAGGCTGATC-3’  (reverse).  Then, 
the sequence was inserted into pGCSIL-GFP lentivi-
rus vector with T4 DNA ligase. The ligated vector was 
transformed  into  competent  Escherichia  coli  DH5 
cells.  To  produce  lentiviral  vectors,  293T  cells  were 
co-transfected  with  the  three  vector  plasmids: 
pGC-LV、pHelper 1.0 and pHelper 2.0. For lentiviral 
transduction, A549 cells were plated at a concentra-
tion of 1×106 cells in 25 mL flask to reach 60–80% 
confluence after overnight culture and were then in-
fected  at  MOI  of  20  in  the  presence  of  polybrene 
(5μg/ml).  Positively  infected  cells  were  sorted  by 
FACS to be continued to culture. The level of miR-7 
was detected by realtime PCR. 
Migration assay 
Migration  of  the  cells  infected  with 
miR-7-GFP-LV lentivirus or its control were measured 
by counting the number of cells that migrated through 
Transwell inserts with 3μm pores, as described pre-
viously.  Cells  were  trypsinized,  and  200μl  of  cell 
suspension  (1×106  cells/ml)  from  each  treatment 
were added in triplicate wells. After 24h incubation, 
the cells that had migrated through the filter into the 
lower wells were quantitated by gentian violet assay 
and expressed as the total cell numbers in the lower 
wells.  
Tumorigenicity assay in nude mice 
Nude mice (4–6 weeks old) were used for xeno-
graft  studies.  MiR-7  and  miR-NC  transfected  A549 
cells (3×106 in matrigel) were injected s.c. into either 
side of the posterior flank of the same female nude 
mouse.  After  7  days,  the  tumor  surface  areas  were 
measured with a vernier caliper at weekly intervals. 
The formula (L/2)×(W/2)×π (where L is maximum 
diameter of each tumor, and W is the length at right 
angles to L) was used to calculated the tumor surface 
areas as previously described[17, 18]. 
MiRNA target prediction  
Putative miRNA target genes were searched by 
application  of  miRanda  (http://cbio.mskcc.org/ 
microrna [19], then calculated the binding free energy 
and  analyzed  biding  sites  on  the  website  of 
http://bibiserv.techfak.uni-bielefeld.de/rnahybrid 
[20]). 
Luciferase assay 
A549 cells were transfected with  BCL-2 3’UTR 
plasmid, Renilla luciferase pRL-TK vector (Promega 
USA),  and  miR-7  mimic  or  miR-NC  mimic  using 
lipofectamine  2000  reagent  (Invitrogen,  USA)  ac-
cording to the manufacturer’s protocol. Luminescence 
was assayed 48 hours later using the Dual-Luciferase 
Reporter Assay System (Promega USA) according to 
the  manufacturer's  instructions.  Results  were  nor-
malized  to  the Renilla  luminescence from  the same 
vector  and  shown  as  the  ratio  between  the  various 
treatments and cells transfected with control vector.  
Western blot analysis 
Proteins extracted from cells were immunoblot-
ted  with  different  antibodies  following  a  published 
protocol[17].  The  primary  antibodies  used  were 
BCL-2  (1:5000  dilutions)  and  GAPDH  (1:5000  dilu-
tions) (Cell Signaling, Danvers, MA, USA).  
Statistical analysis 
Data  were  expressed  as  Mean±SEM  of  three 
independent  experiments.  For  all  statistical  tests, 
PRISM 5.0 (GraphPad Software Inc., San Diego, CA, 
USA) was used. P values less than 0.05 were consid-
ered statistically significant. 
Results 
miR-7 was frequently downregulated in NSCLC 
cell lines 
To  assess  the  biological  role  of  miR-7  in  lung 
cancer  cells,  we  first  examined  the  expression  of 
miR-7 in lung cancer cell lines including A549, H1299, Int. J. Biol. Sci. 2011, 7 
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H1355  and  H460  cells.  Since  most  of  the  miR-
NA-related studies on cancers are based on the dif-
ferent  expression  of  miRNAs  in  cancer  cells  versus 
normal cells[21], we compared miR-7 expression be-
tween these lung cancer cell lines and normal human 
fetal  lung  fibroblast  cell  line  MRC5  using  realtime 
RT-PCR.  As  a  result,  miR-7  showed  significantly 
lower expression in human non-small cell lung cancer 
A549, H1299 and H1355 cells than in MRC5 cells (Fig. 
1). However, expression of miR-7 exhibited no signif-
icant difference in large cell cancer H460 cells com-
pared to MRC5 cells. These data suggest that expres-
sion of miR-7 may vary in different lung cancer cell 
types and is frequently down-regulated in NSCLC cell 
lines. Therefore, it indicated that the downregulation 
of miR-7 might be involved in lung carcinogenesis.  
 
Fig.1 Expressions of miR-7 are downregulated in NSCLC 
cell  lines.  The  miR-7  expression  levels  of  A549,  H1299, 
H1355, H460 and MRC5 cells were detected by realtime 
RT-PCR. The relative expression of miR-7 was normalized to 
the endogenous control U6. Each sample was analyzed in 
triplicate. (**p<0.01, ***p<0.001). 
 
Overexpression of miR-7 suppressed prolifera-
tion and induced apoptosis of A549 cells in vitro 
We next investigated the influence of miR-7 on 
phenotypes of A549 cells. We transiently transfected 
A549  cells  with  mature  miR-7  mimic  (miR-7).  As  a 
control,  cancer  cells  were  transfected  with  negative 
control mimic (miR-NC) without specifically targeting 
any human gene products. After 48h, cells transfected 
with miR-7 were found to grow more slowly than the 
negative  control  and  vehicle  group  (Fig.  2A).  In 
CCK-8 proliferation assay, A549 cells also exhibited 
reduced  cell  proliferation  in  the  presence  of  miR-7 
(Fig.  2B)  with  a  dose-dependent  manner  (Fig.S1). 
However, miR-7 showed no significant influence on 
cell growth of MRC5 cells (Fig. 2C).  
To further understand whether the reduced cell 
growth was due to apoptosis, we studied the apopto-
sis  of  cells  following  Annexin  V/PI  assay,  DAPI 
staining  and  caspase-3/7  assay.  A549  cells  were 
transfected with various doses of miR-7 mimic (from 0 
to 50nM) or negative control mimic in low-serum (3%) 
DMEM  for  48h  and  subsequently  analyzed  by  An-
nexin  V/PI  assay.  We  observed  a  dose-dependent 
increase  of  cell  apoptosis  after  miR-7  transfection 
(Fig.S2).Similarly, the percentage of cells with apop-
totic  nuclei  significantly  increased  in  miR-7-  trans-
fected group compared to the control in DAPI stain-
ing (Fig. 2D), suggesting the induction of apoptosis by 
miR-7. We also found substantial increases in the ac-
tivities of caspase-3 and caspase-7 after miR-7 trans-
fection (Fig. 2E). Moreover, the effect of miR-7 on ac-
tivities of caspase-3 and caspase-7 could be rescued by 
miR-7 inhibitor (Fig. 2E). Together, these results in-
dicated  that  the  inhibition  of  cell  growth  by  miR-7 
was associated with increased apoptosis. 
miR-7 inhibits migration of A549 cells  
Cell migration is an essential process in cancer 
metastasis. To assess the effect of miR-7 on migration 
of A549 cells, we first established a stable miR-7 ex-
pressing  A549  cell  line  (miR-7-GFP-LV)  by  pGC-
SIL-GFP  lentivirus  vector  through  lentiviral  trans-
duction.  We  observed  a  significant  decrease  in  cell 
migration  in  miR-7-GFP-LV  cells  compared  with 
mock vector control ones (control-GFP-LV) (Fig. 3A). 
We further analyzed the MMP-2 and MMP-9 expres-
sion by realtime RT-PCR. It showed a significant re-
duction  of  MMP-2  and  MMP-9  expression  in 
miR-7-GFP-LV cells (Fig. 3B).  
miR-7 inhibited tumor growth of A549 cells in 
vivo. 
Given the suppression of A549 cell viability by 
miR-7  in  vitro,  we  further  evaluated  whether  in-
creased level of miR-7 could inhibit tumor growth of 
A549 cells in vivo. A549 cells were transfected either 
with  miR-7  or  miR-NC.  Six  hours  later,  they  were 
implanted subcutaneously into either posterior flank 
of the same nude mice (3 x106 cells per injection site). 
A549 cells transfected with miR-NC formed tumors 15 
days after implantation, while A549 cells transfected 
with miR-7 partially failed to grow 15 days after in-
jection, and exhibited a marked reduction in tumor 
size  at  week  8  post-implantation  compared  to  the 
control group (Fig4.A/B). These data indicated that 
elevated miR-7 level in A549 cells markedly reduced 
their ability to form tumors.  Int. J. Biol. Sci. 2011, 7 
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Fig 2. Overexpression of miR-7 suppressed cell proliferation and induced apoptosis of A549 cells. (A) A549 cells were 
transfected with 50nM of miR-7 mimic (miR-7) or negative control mimic (miR-NC), and incubated for 48h. Cell morphology 
was detected by a microscope. (B) Cell proliferation was measured by CCK-8 assay. (C) MRC5 cells were transfected with 
50nM of miR-7 or miR-NC. CCK-8 assay was performed at 48h after transfection. (D) A549 cells were transfected with 50nM 
of miR-7, miR-NC or along with miR-7 inhibitor (200nM). Cells were then incubated with low-serum (3%) DMEM mediums for 
48h. Morphology of apoptotic cell nuclei was observed by DAPI staining using a ﬂuorescence microscope. (E) Subsequently, 
activities of caspase-3 and caspase-7 were examined by caspase 3/7 assay. Data are representative of three independent 
experiments. (**p<0.01, ***p<0.001).  
 
Fig 3. miR-7 inhibits migration of A549 cells. (A)Stable miR-7 expressing A549 cells miR-7-GFP-LV and mock vector control 
cells control-GFP-LV were allowed to migrate on transwell inserts for 24h. The cells that had migrated through the filter into 
the lower wells were quantitated by gentian violet assay and were expressed as the total cell numbers of lower wells. 
(B)MMP-2 and MMP-9 expressions of miR-7-GFP-LV and control-GFP-LV cells were measured by realtime RT-PCR and nor-
malized with respect to endogenous GAPDH and were expressed as fold change compared with control. Data are repre-
sentative of two independent experiments. (*p<0.05, ***p<0.001). 
 Int. J. Biol. Sci. 2011, 7 
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Fig 4. miR-7 inhibited A549 cells tumor growth in vivo. miR-7 and miR-NC mimic transfected A549 cells (3×10
6) were 
injected s.c. into either side of the posterior flank of the same female nude mouse respectively (as indicated).(A) A pho-
tograph is shown 8 weeks after tumor cell implantation. (B) Tumor sizes are shown as Mean + SEM. Three mice were used in 
each time and repeated twice, for a total of six mice. Data are representative of two independent experiments (***p<0.001). 
 
 
 
BCL-2 emerged as a novel target for miR-7 
According  to  the  previous  data,  we  hypothe-
sized that miR-7 might inhibit the malignant pheno-
type of A549 cells by regulating genes that control cell 
proliferation or apoptosis. Thus, we tried to search for 
the  target  genes  of  miR-7  by  algorithm  of  PicTar, 
Target  Scan  and  miRanda.  Among  them,  BCL-2,  a 
molecule in the anti-apoptotic family, was found to 
have putative miR-7 binding sites within its 3’UTR in 
database of miRanda (Fig.5A). 
It  is  well  known  that  miRNAs  cause  mRNA 
cleavage  or  translational  repression  by  forming  im-
perfect base pairing with the 3’UTR of target genes. To 
directly  test  whether  miR-7  can  repress  BCL-2 
through  direct  3’UTR  interactions,  we  cloned  the 
3’UTR of BCL-2 into a reporter plasmid downstream 
from luciferase and performed reporter assays using 
A549  cells.  No  significant  differences  of  luciferase 
activities  were  found  between  the  vehicle  control 
group and negative control one (Data not shown). As 
shown in Fig.5B, miR-7 repressed the activity of lu-
ciferase fused to the WT BCL-2 3’UTR, while it failed 
to repress the mutated one. These results indicate that 
miR-7  may suppress  BCL-2 expression by targeting 
the 3’-UTR of BCL-2 mRNA. 
To assess whether miR-7 had a functional role in 
downregulation  of  endogenous  BCL-2  expression, 
A549 cells were transfected with miR-7 mimic for 24h 
and then analyzed the BCL-2 expression by realtime 
PCR.  As  a  result,  overexpression  of  miR-7  signifi-
cantly  reduced  the  expression  of  BCL-2  at  mRNA 
level (Fig.5C). Protein level of BCL-2 expression was 
further  analyzed  by  western  blot.  Compared  with 
control  groups,  BCL-2  expression  was  remarkably 
reduced  in  response  to  miR-7  transfection  for  48h 
(Fig.5D). Taken together, these results suggested that 
miR-7  could  decrease  expression  of  BCL-2  through 
direct 3’UTR interactions. 
Inhibition of BCL-2 induced apoptosis of A549 
cells 
Since miR-7 could decrease expression of BCL-2, 
we would like to further investigate the influence of 
such kind of alteration on A549 cells. Blocking BCL-2 
with  its  inhibitor  ABT-737(10μM)  significantly  de-
creased the cell viability of A549 cells in CCK-8 assay 
(Fig6A). The percentage of cells with apoptotic nuclei 
was also increased in DAPI staining (Fig.6B). Mean-
while, significant increases in activities of caspase-3 
and caspase-7 were observed after ABT-737 treatment 
(Fig.6C). These results were consistent with the effect 
of miR-7 on A549 cells (Fig2.A/B/D), providing fur-
ther  evidence  that  BCL-2  may  be  involved  in 
miR-7-mediated  growth  suppression  and  apoptosis 
induction of A549 cells. Accordingly, identiﬁcation of 
BCL-2 as a novel miR-7 target gene may explain, at 
least in part, the molecular mechanism of the tumor 
suppressor miR-7.  Int. J. Biol. Sci. 2011, 7 
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Fig 5. miR-7 downregulated BCL-2 expression by directly targeting its 3’-UTR. (A) BCL-2 3’-UTR and corresponding 
fragments were inserted into the region immediately downstream of the luciferase gene in pGL3-con vector and validated 
by DNA sequencing. The sequences of predicted miR-7 binding sites within the BCL-2 3’-UTR, including wild-type UTR or UTR 
segments containing mutant (dotted lines) binding site are shown. (B) Relative luciferase activity was analyzed after 
co-transfection of miR-7 or miR-NC with the above reporter plasmids along with an endogenous control Renilla luciferase 
pRL-TK vector in A549 cells. (C) A549 cells were transfected either with miR-7 or miR-NC for 24 hours. BCL-2 mRNA levels 
were measured by realtime RT-PCR, normalized with endogenous GAPDH and expressed as fold change compared with 
control. (D) BCL-2 protein levels were examined by western blots using GAPDH as a loading control (one of two similar blots 
is  shown).  Results  are  shown  as  Mean  ±  SEM.  Data  are  representative  of  three  independent  experiments 
(*p<0.05,***p<0.001). 
 
 
 
Fig 6. BCL-2 inhibitor ABT737 induced apoptosis of 
A549 cells. A549 cells were treated with BCL-2 in-
hibitor ABT737 (10μM) or DMSO (vechicle control) for 
24h. (A) Cell viability was detected by CCK-8 assay. 
(B) Apoptotic nuclei were analyzed by DAPI staining. 
The  inserted  enlarged  micrograph  shows  the  mor-
phology of the apoptotic cell nuclei. (C) Activities of 
caspase-3/7  were  measured  by  a  Caspase-Glo  3/7 
assay  kit.  Data  are  representative  of  three  inde-
pendent experiments (**p<0.01, ***p<0.001). 
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Discussion 
Increasing  data  have  indicated  miRNAs  to  be 
critical regulators in cancer-related processes[5, 8, 22]. 
MiRNA expression shows close correlation with var-
ious cancers[7, 9, 23, 24]. They are thought to function 
as  either  tumor  suppressors  or  oncogenes.  During 
tumorigenesis  and  development,  overexpressed 
miRNAs  may  potentially  target  tumor  suppressor 
genes,  whereas  downregulated  miRNAs  would 
mostly  regulate  oncogenes[24-26].  For  example, 
miR-155, which is highly expressed in breast cancer, 
promotes tumor cell growth by downregulating the 
suppressor  of  cytokine  signaling  1  gene[27].  Con-
versely,  miR-7,  which  has  low  expression  in  brain, 
breast cancer, and pituitary adenoma, often acts as a 
tumor suppressor[12-15]. In NSCLC tissues,  Dunca-
vage  et  al  also  showed  that  miR-7  expression  was 
significantly  decreased  in  recurrent  tumors[28].This 
result was consistent with the reduction of miR-7 level 
in NSCLC cell lines in our study. Moreover, we ob-
served  a  significant  inhibition  on  cell  growth  by 
overexpression  of  miR-7,  suggesting  miR-7  to  be  a 
tumor  suppressor  in  NSCLC  cell  lines.  However,  a 
recent  report  showed  that  miR-7  promoted,  rather 
than  inhibited,  cell  growth  and  tumor  formation in 
another lung cancer line CL1-5[29]. Therefore, the role 
of miR-7 may be different in various cancer types. 
The fundamental function of miRNA is to regu-
late their targets by direct cleavage of the mRNA or by 
inhibition of protein synthesis through complementa-
rity with their target 3’-UTRs[3, 6]. Several targets of 
miR-7 have been identified so far, such as IRS1 (Insu-
lin  Receptor  Substrate  1),  IRS2,  EGFR  (Epidermal 
Growth Factor Receptor), RAF1 (v-raf-1 murine leu-
kaemia  viral  oncogene  homologue  1)  and  PAK1 
(p21/CDC42/RAC1-Activated  Kinase  1)[12,  14,  15]. 
On  the  basis  of  bioinformatics  analysis,  we  further 
predicted a number of additional miR-7 targets. Our 
present experimental results suggested BCL-2 to be a 
novel  regulated  molecule  of  miR-7  in  A549  cells. 
Overexpression  of  miR-7  significantly  reduced  the 
endogenous BCL-2 mRNA and protein levels. MiR-7 
also reduced the relative luciferase activity of reporter 
containing  the  potential  binding  sites  on  3'-UTR  of 
BCL-2 in reporter assays while it failed to repress the 
relative  luciferase  activity  of  reporter when  the  po-
tential binding sites were mutated. Therefore,  these 
results suggested that miR-7 decreased the expression 
of BCL-2 through direct 3’UTR interactions. 
BCL-2 family proteins are key regulators of the 
apoptotic process [30, 31]. The members of this family 
can  be  divided  into  two  groups  with  contradictory 
biological  functions,  one  with  anti-apoptotic  (i.e. 
BCL-2,  Bcl-XL,  Bcl-w)  and  the  other  with 
pro-apoptotic  (i.e.Bax,  Bim,  Bid)  properties[30,  31]. 
BCL-2  predominantly  localized  in  mitochondria 
which is the central coordinator of both intracelluar 
and  extracellular  signals  mediating  caspa-
se-dependent  and  caspase-independent  cell 
death[32-34]. Recently, it has been reported that in-
duction  of  mitochondrial  apoptosis  requires  the  in-
volvement of BCL-2[35, 36]. Thereby, it is emerging 
with an important role in tumorigenesis by blocking 
apoptosis[37, 38]. We found that inhibition of BCL-2 
by its inhibitor ABT 737 significantly induced apop-
tosis of A549 cells, which is consistent with the effect 
of miR-7.  Meanwhile,  miR-7 could decrease the  ex-
pression of anti-apoptotic molecule BCL-2. These re-
sults indicated that the downregulation of BCL-2 by 
miR-7 may be involved in the pro-apoptotic function 
of miR-7. Therefore, identiﬁcation of BCL-2 as a novel 
miR-7 target gene may explain, at least in part, the 
molecular mechanism of the tumor suppressor miR-7. 
In summary, this study further extends the bio-
logical role of miR-7 in NSCLC A549 cells and for the 
first time identifies BCL-2 as a novel target possibly 
involved in miR-7-mediated growth suppression and 
apoptosis induction of A549 cells. These findings may 
provide a basic rationale for the use of miR-7 in the 
treatment of NSCLC. 
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Figures 
 
Fig. S1 miR-7 suppressed the growth of A549 cells in a dose-dependent manner. A549 cells were transfected with various 
doses of miR-7(from 0 to 100nM) in low-serum (3%) DMEM for 48h and then cell growth was detected by CCK-8. 
 
 
 
 
 
Fig. S2 miR-7 induced apoptosis of A549 cells in a dose-dependent manner. A549 cells were transfected with various 
doses of miR-7(from 0 to 50nM) in low-serum (3%) DMEM for 48h and then cell apoptosis was detected by Annexin V /PI assay. 
 